Patient Information This brochure provides etails about the AROATXN2-1001 Study for individuals with spinocerebellar ataxia type 2 (SCA2)d. It aims to help potential participants decide whether they or someone they know may want to join the study. Eligibility Criteria You may be eligible to participate if you: Are between 18...
My story with Friedreich’s Ataxia (4 of 4) Hello amigos! At 18, when I came of age, I had to leave CHEO to “stand on my own two feet”. Since CHEO only treats children, I had to accept the fact that I was one, despite being 5 feet tall. It...
The Ataxia Canada Foundation thanks CDPQ for the financial support provided to the research. This project aimed to reprogram patient-derived cells into induced pluripotent stem cells (iPSC) for the study of ARCA1, a disease for which there is a significant lack of representative cellular models. Impact of this Research: Specific...
Conversation with women and men engaged in our foundation. Today, we present Sébastien HUYNH | LinkedIn. AC: Can you introduce your professional background? SH: My career has allowed me to develop broad skills in management, finance, and accounting. Having grown up in France, I have had the opportunity to work...
Posted on: 2023-10-18– Posted by: Ataxia Canada – Category: publications Deadline: November 18 2023 Dear Members, At the next annual general assembly on December 3rd 2023, we will renew and/or elect members to the Board of Directors. We are seeking to solicit nominations of bilingual candidates that satisfy some of...
The study is being conducted with multiple sites in the United States and Canada seeking to recruit approximately 9 participants aged 18-40 with a diagnosis of FA-associated cardiomyopathy. The study will be conducted by Dr. Antoine Duquette at the CHUM in Montreal. The choice of Montreal as a site reflects...
U.S. Food & Drug Administration Approves Reata Pharmaceuticals’ SKYCLARYS™ (Omaveloxolone) for the Treatment of Adults and Adolescents Aged 16 Years and Older with FA Montreal,QC ., February 28, 2023 – This week marks the approval of the first medication to treat Friedreich’s Ataxia (FA), a milestone for the FA...